Skip Navigation



European Heart Journal Advance Access published online on June 9, 2008
European Heart Journal, doi:10.1093/eurheartj/ehn257
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/14/1699    most recent
ehn257v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kamphuisen, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kamphuisen, P. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Thrombogenicity in patients with percutaneous coronary artery intervention and dual antiplatelet treatment

Pieter W. Kamphuisen*

Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands

* Corresponding author. Tel: + 31205665976, Fax: + 31206968833, Email: p.w.kamphuisen@amc.uva.nl

This editorial refers to ‘Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad’ by Y. Yano et al. doi:10.1093/eurheartj/ehn027

The first 10% of the full text of this article appears below.

Antiplatelet drugs are very effective and widely used for both the initial management of acute coronary syndrome and the long-term prevention of myocardial infarction, stroke, and peripheral artery disease. Dual antiplatelet therapy with clopidogrel and aspirin is more effective than aspirin monotherapy in most patients with cardiovascular disease.1,2 In addition, in patients with percutaneous coronary artery intervention (PCI), the addition of cilostazol on top of the dual antiplatelet treatment further increases clinical efficacy, as was shown in the CREST (Cilostazol for RESTenosis) trial.3 Finally, in a large randomized trial in 13 608 patients who were scheduled . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad
Yuichiro Yano, Tsukasa Ohmori, Satoshi Hoshide, Seiji Madoiwa, Keiji Yamamoto, Takaaki Katsuki, Takeshi Mitsuhashi, Jun Mimuro, Kazuyuki Shimada, Kazuomi Kario, and Yoichi Sakata
EHJ 2008 29: 1729-1738. [Abstract] [FREE Full Text]